As of Apr 20
| +0.08 / +1.62%|
The 3 analysts offering 12-month price forecasts for Redhill Biopharma Ltd have a median target of 20.00, with a high estimate of 51.42 and a low estimate of 17.00. The median estimate represents a +299.20% increase from the last price of 5.01.
The current consensus among 4 polled investment analysts is to Buy stock in Redhill Biopharma Ltd. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.